Montpellier, February 2026 — Aceso Therapeutics and the Université de Montpellier, in collaboration with the PhyMedExp laboratories, announce a research collaboration dedicated to the development of new therapeutic approaches for cystic fibrosis.
This collaboration aims to accelerate the development of the ACT-101 program, an innovative therapy based on antisense oligonucleotides (ASO), currently in advanced preclinical development, with an IND filing planned for 2027.
Cystic fibrosis affects more than 100,000 people worldwide. It is a rare genetic disease caused by mutations in the CFTR gene, primarily impacting the lungs. Despite recent therapeutic advances, around 20% of patients still have no effective treatment option.
ACT-101 targets the underlying genetic mechanisms of the disease to provide a therapeutic option for patients who do not respond to current treatments.
This project is part of an innovation ecosystem supported by the Occitanie region and Bpifrance, combining academic research and industrial development.
Aceso Therapeutics – information available upon request
Press contact: contact@aceso-therapeutics.com
LinkedIn: https://www.linkedin.com/company/aceso-therapeutics/